Get started
Author

Alexandra Maria Poos

Observed names: A. M. Poos, Alexandra M Poos, Alexandra M. Poos, Alexandra Poos, Alexandra Pos, Poos Alexandra, Poos, Alexandra, Poos, Alexandra M.
Observed institutions: University of Miami, German Cancer Research Center, Norwegian University of Science and Technology, Heidelberg University, University Hospital Heidelberg, Technische Universität Darmstadt, Dana-Farber Cancer Institute, Jena University Hospital, Sylvester Comprehensive Cancer Center, Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI), Weill Cornell Medicine, Center for Sepsis Control and Care, University of Bologna
ORCID: 0009-0009-4325-3933
Observed ORCID: 0009-0009-4325-3933
OpenAlex ID: A5034285292
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
2021 · Stephan M. Tirier, Jan-Philipp Mallm, et al. · Nature Communications · 146
PDF
Genomic Classification and Individualized Prognosis in Multiple Myeloma
2024 · Francesco Maura, Arjun Raj Rajanna, et al. · Journal of Clinical Oncology · 130
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
2022 · Leo Rasche, Carolina Schinke, et al. · Nature Communications · 78
PDF
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
2022 · Carolina Schinke, Alexandra M. Poos, et al. · Blood Advances · 65
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
2023 · Alexandra M. Poos, Nina Prokoph, et al. · Blood · 64
PDF
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks
2019 · Jan‐Philipp Mallm, Murat Iskar, et al. · Molecular Systems Biology · 57
PDF
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
2023 · Elias K. Mai, Stefanie Huhn, et al. · Blood Cancer Journal · 55
PDF
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
2023 · Nicola Giesen, Manik Chatterjee, et al. · Blood · 48
PDF
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
2023 · Lukas John, Alexandra M. Poos, et al. · Nature Communications · 47
PDF
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
2025 · Raphael Lutz, Alexandra M. Poos, et al. · Science Immunology · 25
Expression of CCCTC‐binding factor (CTCF) is linked to poor prognosis in prostate cancer
2019 · Doris Höflmayer, Amélie Steinhoff, et al. · Molecular Oncology · 20
PDF
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
2025 · Benjamin Diamond, Linda Baughn, et al. · Blood · 16
PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power
2022 · Alexandra Poos, Cornelia Schroeder, et al. · Cancers · 16
PDF
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
2024 · Anthony M. Cirrincione, Alexandra M. Poos, et al. · Blood · 15
PDF
Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
2022 · Luca Heinemann, Klara Maria Möllers, et al. · Frontiers in Oncology · 15
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
2025 · Francesco Maura, Marcella Kaddoura, et al. · Nature Genetics · 14
PDF
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma
2024 · Sarah Schreiner, Natalie Berghaus, et al. · Amyloid · 12
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
2022 · Odai Darawshi, Barbara Muz, et al. · Cell Death and Disease · 12
PDF
Mixed Integer Linear Programming based machine learning approach identifiesregulatorsof telomerase in yeast
2016 · Alexandra M. Poos, André Maicher, et al. · Nucleic Acids Research · 10
PDF
Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma
2020 · Alexandra M Poos, Nicola Giesen, et al. · Blood · 9
Dissecting telomere maintenance mechanisms in pediatric glioblastoma
2017 · Katharina I. Deeg, Inn Chung, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 8
PDF
The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients - from Sub-Clonal Architecture to the Immune Microenvironment
2021 · Lukas John, Alexandra Poos, et al. · Blood · 6
Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
2022 · Francesco Maura, Arjun Raj Rajanna, et al. · Blood · 5
Modelling TERT regulation across 19 different cancer types based on the MIPRIP 2.0 gene regulatory network approach
2019 · Alexandra M. Poos, Theresa Kordaß, et al. · BMC Bioinformatics · 5
PDF
Loss of CCAAT‐enhancer‐binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers
2018 · Sarah Minner, Jannes Lutz, et al. · The Prostate · 5
Works count: 88
Citation count: 928
H-index: 15
I10-index: 19
Year
Topic
Type